Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | KDM5C | P41229 | 1/20 | 0.43 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.43 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | CASP2 | P42575 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2618704 | 0.88 | KDM4E (0.46) | KDM4EKDM5CPHF8KDM2ALMNA | |
| SCHEMBL2618710 | 0.86 | ALDH1A1 (0.44) | KDM4EKDM5CPHF8KDM2ACA1 | |
| SCHEMBL2618713 | 0.86 | TSHR (0.41) | KDM4EKDM5CPHF8KDM2ALMNA | |
| SCHEMBL13302374 | 0.85 | ALDH1A1 (0.39) | KDM4EKDM5CPHF8KDM2ALMNA | |
| SCHEMBL13302376 | 0.85 | ALDH1A1 (0.47) | KDM4EKDM5CPHF8KDM2ATSHR | |
| SCHEMBL1160518 | 0.83 | KDM4E (0.59) | KDM4EKDM5CPHF8KDM2ALMNA | |
| SCHEMBL2618703 | 0.82 | KDM4E (0.48) | KDM4EKDM5CPHF8KDM2ALMNA | |
| SCHEMBL13492303 | 0.80 | LMNA (0.42) | KDM4EKDM5CPHF8KDM2ALMNA | |
| SCHEMBL1627990 | 0.79 | KDM4E (0.48) | KDM4EKDM5CPHF8KDM2ALMNA | |
| SCHEMBL13492301 | 0.79 | CTSD (0.47) | TSHRALDH1A1CTSDCASP2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8647670-B2 | Biocompatible rapid-gelating hydrogel and associated preparation method of spray | BIOREGEN BIOMEDICAL (CHANGZHOU) CO., LTD. (CN) | 2014-02-11 | — | — | US | disclosed |
| US-8647670-B2 | Biocompatible rapid-gelating hydrogel and associated preparation method of spray | BIOREGEN BIOMEDICAL (CHANGZHOU) CO., LTD. (CN) | 2014-02-11 | — | — | US | disclosed |
| US-8158754-B2 | Multiple modified derivatives of gelatin and crosslinked material thereof | BIOREGEN BIOMEDICAL (CHANGZHOU) CO., LTD. (CN) | 2012-04-17 | — | — | US | disclosed |
| US-8124757-B2 | Thiol-modified macromolecule derivatives and cross-linked materials thereof | BIOREGEN BIOMEDICAL (CHANGZHOU) CO., LTD. (CN) | 2012-02-28 | — | — | US | disclosed |
| US-8067636-B2 | Dihydrazide compounds, preparation and uses thereof | BIOREGEN BIOMEDICAL (SHANGHAI) CO., LTD (CN) | 2011-11-29 | — | — | US | disclosed |
| US-20100152423-A1 | THIOL-MODIFIED MACROMOLECULE DERIVATIVES AND CROSS-LINKED MATERIALS THEREOF | BIOREGEN BIOMEDICAL (CHANGZHOU) CO., LTD. (CN) | 2010-06-17 | — | — | US | disclosed |
| US-20100144902-A1 | BIOCOMPATIBLE RAPID-GELATING HYDROGEL AND ASSOCIATED PREPARATION METHOD OF SPRAY | BIOREGEN BIOMEDICAL (CHANGZHOU) CO., LTD. (CN) | 2010-06-10 | — | — | US | disclosed |
| US-20100048952-A1 | DIHYDRAZIDE COMPOUNDS, PREPARATION AND USES THEREOF | BIOREGEN BIOMEDICAL (CHANGZHOU) CO., LTD. (CN) | 2010-02-25 | — | — | US | disclosed |
| US-20090306345-A1 | MULTIPLE MODIFIED DERIVATIVES OF GELATIN AND CROSSLINKED MATERIAL THEREOF | BIOREGEN BIOMEDICAL (CHANGZHOU) CO., LTD. (CN) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048952-A1 | DIHYDRAZIDE COMPOUNDS, PREPARATION AND USES THEREOF | GRHPR, HRH4, HRH2 | KDM4E 2190/4885KDM5C 3898/4885PHF8 1071/4885 |
| US-20100144902-A1 | BIOCOMPATIBLE RAPID-GELATING HYDROGEL AND ASSOCIATED PREPARATION METHOD OF SPRAY | CSTB, CAPG, F12 | KDM4E 2989/4885KDM5C 1626/4885PHF8 4283/4885 |
| US-20100152423-A1 | THIOL-MODIFIED MACROMOLECULE DERIVATIVES AND CROSS-LINKED MATERIALS THEREOF | PTMS, TMT1A, EPCAM | KDM4E 2135/4885KDM5C 2657/4885PHF8 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.